Showing results (51-60 of 103) with videos related to
Sort By:
Pageof 11
Blood|May 1, 1992
Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a rare variant with a propensity for unusual sites of involvementW F Kern, C M Spier, E H Hanneman, et al.Blood|February 15, 1995
A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group studyR I Fisher, S Dahlberg, B N Nathwani, et al.Cancer|August 15, 1985
Chemohormonal therapy for advanced breast cancer with tamoxifen, adriamycin, and cyclophosphamide (TAC)F R Ahmann, S E Jones, T E Moon, et al.International Journal of Radiation Oncology, Biology, Physics|November 15, 1993
Radiation therapy salvage of Hodgkin's disease following chemotherapy failureB R Leigh, K A Fox, C F Mack, et al.Investigational New Drugs|January 1, 1994
Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer. A Southwest Oncology Group studyJ O Atiba, S J Green, H E Hynes, et al.Seminars in Hematology|April 1, 1987
Southwest oncology group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomasR I Fisher, T P Miller, B W Dana, et al.Investigational New Drugs|January 19, 2000
Phase II trial of menogaril in non-Hodgkin's lymphomas: a Southwest Oncology Group trialD F Moore, T D Brown, M LeBlanc, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1993
Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapyB W Dana, S Dahlberg, B N Nathwani, et al.Leukemia & Lymphoma|July 27, 2016
Prediction of Outcome in Diffuse Large Cell Lymphoma by the Major Histocompatibility Complex Class II (HLA-DR, DP, DQ) and Class I (HLA-A, B, C) PhenotypeJ A Rybski, C M Spier, T P Miller, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 11, 1991
Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomasR I Fisher, D L Longo, V T DeVita, et al.Pageof 11